CLINICAL_TRIALS
trial_result
· 2021-10-29
Clinical Trial Update: BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) [Phase 1, Phase 2]
Summary
A phase 1/2 trial evaluating a BRAF/MEK/EGFR inhibitor combination in colorectal cancer has completed enrollment with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-29